Third Harmonic Bio director reports option cancellation tied to liquidation
Rhea-AI Filing Summary
Thomas P. Soloway, a director of Third Harmonic Bio, Inc. (THRD), reported a change in beneficial ownership related to derivative securities on 08/11/2025. The filing shows a reported transaction code J(2) cancelling 120,166 stock options tied to common stock. The form states the cancellation reflects payment of a liquidation distribution of $5.35 per share less the exercise price and that the cancellation occurred in connection with the dissolution of the issuer. Following the reported transaction, the filing lists 0 shares beneficially owned related to these options.
Positive
- Disclosure of liquidation distribution amount ($5.35 per share) provides clear numeric detail on payout calculation
- Form 4 filed and signed indicating procedural compliance with Section 16 reporting
Negative
- Cancellation of 120,166 options reduces insider equity holdings and signals termination of those compensation rights
- Issuer dissolution implies shareholders may receive limited recovery and equity is being wound up
Insights
TL;DR: Director reported cancellation of 120,166 options tied to a liquidation distribution amid issuer dissolution.
The Form 4 documents a non-derivative/derivative-related transaction dated 08/11/2025 recorded under code J(2), indicating cancellation connected to the issuer's dissolution. The disclosure that a $5.35 per share liquidation distribution was paid net of exercise price is material to insider recovery from winding-up proceeds. This filing is procedural and compliant in format; it does not provide details on remaining recoveries, creditor hierarchy, or final distribution timing, which would require other filings.
TL;DR: Insider option cancellation signals wind-down actions but provides limited detail on overall stakeholder impact.
The cancellation of 120,166 options and explicit tie to dissolution demonstrates a formal winding-up affecting equity-linked compensation. For governance and compensation analysis, the event confirms termination of those equity rights and a cash component ($5.35 per share net of exercise). The form lacks context on the total pool of options outstanding, treatment of other holders, or timing of final distributions, constraining a full assessment of investor outcomes.